ABBOTT LABORATORIES (ABT) Earnings History

8 quarters held2/3 transcripts analyzed2/40 figures attested
Connect your agent
PeriodRevenueYoYNet incomeEPS (dil.)Filed
Q2 2026$12.6B+13.0%$928.0M$1.31Aug 5, 2026
LATESTEarnings filing (8-K)10-QFiled Jul 16, 2026, 7:36 AM ET
Earnings call · Jul 16, 2026
Q2 FY26YoY6M FY26
Revenue$12.6B1+13.0%$23.8B
Net income$928.0M-47.8%$2.0B
Op income$1.7B-17.5%$3.0B
EPS (dil.)$1.31+4.0%–
EPS (basic)–––
Gross margin52.5%-0.1pp
Op margin13.4%-5.0pp
Net margin7.4%-8.6pp
  1. [1] “Net Sales $12,593 11,142 13.0” view source

Guidance & outlook

Management guidance

Q2 2026

fy_current

other
7—8
eps_diluted
$5.45—$5.60
Q1 2026$11.2B+7.8%$1.1B$0.61Apr 16, 2026
Earnings filing (8-K)10-QFiled Apr 16, 2026, 7:36 AM ET
Earnings call · Apr 16, 2026transcriptView originalprepared remarksQ&A
Q1 FY26YoY
Revenue$11.2B+7.8%
Net income$1.1B-18.7%
Op income$1.3B-20.6%
EPS (dil.)$0.61-20.0%
EPS (basic)––
Gross margin52.4%-0.4pp
Op margin12.1%-4.3pp
Net margin9.7%-3.1pp
Q4 2025$11.5B+4.4%$1.8B$1.01Jan 22, 2026
Earnings filing (8-K)10-KFiled Jan 22, 2026, 7:35 AM ET
Earnings call · Jan 22, 2026transcriptprepared remarksQ&A
Q4 FY25YoYFY25
Revenue$11.5B+4.4%$44.3B
Net income$1.8B-80.8%$6.5B
Op income$2.3B+17.8%$8.1B
EPS (dil.)$1.01-80.8%$3.72
EPS (basic)–––
Gross margin53.4%+2.6pp
Op margin19.6%+2.2pp
Net margin15.5%-68.6pp
Q3 2025$11.4B+6.9%$1.6B$0.94Oct 15, 2025
Earnings filing (8-K)10-QFiled Oct 15, 2025, 7:33 AM ET
Q3 FY25YoY9M FY25
Revenue$11.4B+6.9%$32.9B
Net income$1.6B-0.1%$4.7B
Op income$2.1B+10.6%$5.8B
EPS (dil.)$0.940.0%$2.70
EPS (basic)–––
Op margin18.1%+0.4pp
Q2 2025$11.1B+7.4%$1.8B$1.01Jul 17, 2025
Earnings filing (8-K)10-QFiled Jul 17, 2025, 7:34 AM ET
Q2 FY25YoY6M FY25
Revenue$11.1B+7.4%$21.5B
Net income$1.8B+36.7%$3.1B
Op income$2.1B+23.0%$3.7B
EPS (dil.)$1.01+36.5%$1.77
EPS (basic)–––
Gross margin52.7%+1.0pp
Op margin18.4%+1.0pp
Net margin16.0%+3.4pp
Q1 2025$10.4B+4.0%$1.3B$0.76Apr 16, 2025
Earnings filing (8-K)10-QFiled Apr 16, 2025, 7:36 AM ET
Q1 FY25YoY
Revenue$10.4B+4.0%
Net income$1.3B+8.2%
Op income$1.7B+22.1%
EPS (dil.)$0.76+8.6%
EPS (basic)––
Gross margin52.8%–
Op margin16.3%–
Net margin12.8%+0.5pp
Q4 2024$11.0B+7.2%$9.2B$5.27Jan 22, 2025
Earnings filing (8-K)10-KFiled Jan 22, 2025, 7:13 AM ET
Q4 FY24YoYFY24
Revenue$11.0B+7.2%$42.0B
Net income$9.2B–$13.4B
Op income$1.9B+7.4%$6.8B
EPS (dil.)$5.27–$7.64
EPS (basic)–––
Gross margin–+0.6pp
Q3 2024$10.6B+4.9%$1.6B$0.94Oct 16, 2024
Earnings filing (8-K)10-QFiled Oct 16, 2024, 7:37 AM ET
Q3 FY24YoY9M FY24
Revenue$10.6B1+4.9%$31.0B
Net income$1.6B+14.6%$4.2B
Op income$1.9B+12.9%$4.9B
EPS (dil.)$0.94+14.6%–
EPS (basic)–––
Gross margin51.4%+1.1pp
Op margin17.5%+1.2pp
Net margin15.5%+1.3pp
  1. [1] “Net Sales $10,635” view source

IR event calendar

This company's IR event calendar has not been harvested yet — an empty result here does NOT mean the company has no IR events.

Filing coverage

54 filings indexed · 55,936 XBRL facts
FilingDatePeriodSectionsTables
10-Q2026-07-28–3143
8-K2026-07-16Q2 202680
10-Q2026-04-29–3034
8-K2026-04-27–10
8-K2026-04-17–10
8-K2026-04-16Q1 202680
8-K2026-03-23–30
DEF 14A2026-03-13–240
8-K2026-03-09–10
8-K2026-02-26–10

Showing the latest 10 of 54 — the full set is in the API.

Related Research

Analysis

Boston Scientific Hit a ROIC Inflection — Then Bet $14.5B on Penumbra

Analysis

The $1.7B Hidden Cost of Stryker's Acquisition Machine

Analysis

Medical Device ROIC Rankings: Why Abbott's 26% Beats Medtronic's 7% (The Gross Margin Paradox)